Therefore, the phosphorylation of SMC2 might be an unknown mechanism for the Pol I inhibitors to treat tumors, indicating that the mutations of SMC2 T574 might reduce the sensitivity of Pol I inhibitors in cancer treatment. The gene discussed is SMC2; the disease is cancer.